Palantir to report; Trump on Nvidia chip exports - what’s moving markets
Investing.com - AtriCure Inc. (NASDAQ:ATRC) shares gained after Citizens reiterated its Market Outperform rating and $60.00 price target following the medical device company’s third-quarter 2025 results. With the stock currently trading at $35.44, this target represents nearly 70% upside potential for the $1.76 billion market cap medical device company.
The company reported revenue growth of 16% year-over-year in the quarter, exceeding consensus estimates by approximately 2%. This performance aligns with AtriCure ’s impressive 16.28% revenue growth over the last twelve months. Adjusted EBITDA more than doubled to $17.8 million compared to $8.0 million in the third quarter of 2024, surpassing Street expectations of $11.7 million. According to InvestingPro, 6 analysts have recently revised their earnings upwards for the upcoming period, suggesting growing confidence in the company’s trajectory.
AtriCure’s Pain Management segment grew 28% year-over-year, while its Appendage Management business increased 21%, driven by momentum from recent product launches including cryoSPHERE Max and AtriClip FLEXMini.
The Open Ablation segment posted 19% year-over-year growth, its highest quarterly growth rate year-to-date despite facing the most challenging year-over-year comparison, as the segment’s flagship product EnCompass continued to gain adoption.
AtriCure raised its full-year 2025 sales guidance by approximately $3 million, matching the amount by which it exceeded third-quarter expectations, with Citizens noting this updated guidance "could be conservative given recent momentum" in the company’s three largest segments.
In other recent news, AtriCure Inc reported its third-quarter 2025 earnings, revealing a notable performance. The company achieved an earnings per share (EPS) of -$0.01, which surpassed the forecasted -$0.11. Additionally, AtriCure’s revenue reached $134.3 million, exceeding the expected $131.25 million. Despite these positive results, the stock experienced a decline in after-hours trading. These developments highlight the company’s ability to outperform earnings expectations while also indicating market reactions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.